The Biocon Board of Directors, meeting on February 12, 2026, approved the un-audited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Critically, the Board also granted in-principle approval to acquire the remaining ~2% equity stake in its subsidiary, Biocon Biologics Limited (BBL), from employees and other shareholders to achieve full ownership. Consideration for this acquisition will be through preferential allotment of Biocon equity shares.
Biocon Announces Quarterly Results and Biocon Biologics Full Integration Approval
Biocon Limited announced the outcomes of its Board meeting held on Thursday, February 12, 2026. The Board primarily approved the financial results and took steps toward completing the full integration of its material subsidiary, Biocon Biologics Limited (BBL).
Financial Performance Highlights (Standalone)
The Board approved the un-audited financial results (standalone and consolidated) prepared as per Ind-AS for the quarter and nine months ended December 31, 2025. Key highlights from the standalone statement for the three months ended 31.12.2025 compared to the previous year include:
- Total Income stood at ₹6,961 Million (vs. ₹6,270 Million in 3 months ended 31.12.2024).
- The loss for the period was (₹778 Million) (vs. a comprehensive income of ₹5,758 Million in the previous year period).
- Basic Earnings Per Share (EPS) was (₹0.57) (not annualised) for the quarter.
Financial Performance Highlights (Consolidated)
The consolidated results also reflected significant activity, particularly related to exceptional items:
- Total Comprehensive Income for the period ended 31.12.2025 was ₹2,539 Million (vs. ₹1,377 Million in 3 months ended 31.12.2024).
- The Profit before tax, interest, depreciation and exceptional items (Operating Margin basis) stood at ₹2,256 Million for the quarter.
- Basic EPS (annualised) for the nine months ended 31.12.2025 was ₹2.01.
Acquisition of Remaining Biocon Biologics Equity
This development follows previous communications regarding the proposed full integration of BBL, which would make it a Wholly Owned Subsidiary (WOS).
The Board has now granted in-principle approval to acquire the remaining ~2% of BBL’s paid-up equity share capital (on a fully diluted basis) from employees of the Biocon Group and other shareholders. The consideration for these shares will be discharged via a preferential allotment of Biocon’s equity shares, subject to further determination and approval by the Board.
Following this final acquisition, BBL is confirmed to become a WOS of Biocon Limited.
Key Events Noted Post-Reporting Date
Subsequent to the reporting date, on January 14, 2026, the Company raised substantial funds through a Qualified Institutional Placement (QIP) of ₹41,500 million. These proceeds are earmarked, in part, to acquire BBL equity shares from Mylan Inc. and to acquire Compulsorily Convertible Debentures (CCDs) from Edelweiss, alongside general corporate purposes.
Furthermore, on January 05, 2026, the Company acquired a significant number of BBL shares from Serum Institute Life Sciences Private Limited and other parties through a share exchange, issuing 79,312,534 equity shares of the Company in return.
Board Meeting Timeline
The Board Meeting commenced at 4:45 P.M. and concluded at 6:45 P.M. on February 12, 2026.
Source: BSE
